Skip to content
DataLookout
Menu

XH-S003-II-101NCT06978699

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Show 8 more changesShow less
    • Eligibility criteria expanded, about 666 words
    • Trial completed
    • Primary completion date changed from estimate of Aug 30, 2025 to Jan 21, 2026
    • Interventions modified
    • Enrollment target: estimated 24 to confirmed 26
    • Start date: Apr 30, 2025 to May 21, 2025
    • Secondary endpoints: 5 to 7
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Changes of hemoglobin compared with baseline
Timeframe: 12 weeks from baseline

Secondary (7)

Proportion of participants with an increase in Hb ≥20g/L compared with baseline (without RBC transfusion);
Changes in Indirect Bilirubin compared to baseline;
Changes in reticulocyte counts compared to baseline;
Proportion of participants with Hb ≥120g/L (without RBC transfusion);
Changes in LDH compared with baseline
Show 2 moreShow less
Proportion of participants with LDH ≤1.5 ULN
Proportion of participants without RBC transfusion

Arms and interventions

High DoseExperimental

XH-S003 Capsule, Administered orally once daily, 125mg, 12-week continuous dosing period.

Medium DoseExperimental

XH-S003 Capsule, Administered orally once daily, 100mg, 12-week continuous dosing period.

Low DoseExperimental

XH-S003 Capsule, Administered orally once daily,50mg, 12-week continuous dosing period.

Drugs: XH-S003 Capsule

Sites

1 site in 1 country

  • TianJin Medical University General HospitalTianjin, China